Published On: Wed, Sep 7th, 2016

Abeona Therapeutics Inc. (ABEO) Trading Up 1.7%

Abeona Therapeutics Inc. (NASDAQ:ABEO) was up 1.7% during mid-day trading on Wednesday . The stock traded as high as $4.85 and last traded at $4.77, with a volume of 94,664 shares. The stock had previously closed at $4.69.
Several equities research analysts have recently issued reports on ABEO shares. FBR & Co restated a “buy” rating on shares of Abeona Therapeutics in a report on Wednesday, June 22nd. Rodman & Renshaw reiterated a “buy” rating and set a $17.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, May 18th. Maxim Group reiterated a “buy” rating and set a $6.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, May 17th. Finally, Cantor Fitzgerald initiated coverage on shares of Abeona Therapeutics in a research report on Wednesday. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $10.25.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The stock’s market cap is $160.68 million. The stock has a 50-day moving average price of $3.50 and a 200 day moving average price of $2.88.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. On average, analysts forecast that Abeona Therapeutics Inc. will post ($0.71) earnings per share for the current year.
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Receive News & Ratings for Abeona Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abeona Therapeutics Inc. and related companies with’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>